Skip to content

LINDA PHARMA

Active
Private limited companyfounded 2025active for 1 yearLeopoldstadplein 16, 1040 Etterbeek, BelgiumKBO/BCE: BE 1025.098.275
Summary

The computed 12-month bankruptcy probability of LINDA PHARMA is 2.1% (moderate). The 2025 annual accounts show equity of €43,688 and a net result of €34,521. Its solvency ranks better than 36% of 22,632 sector peers (NACE 47, financial year 2025). The company has been active since 2025 and the Belgian Official Gazette contains no insolvency or warning signals.

Risk analysisFollow ReportCompare
LINDA PHARMAActiveChecked score 54/100
Risk analysis ReportCompare

Overview

Activity
Retail sale of pharmaceutical products
NACE 47730
2 sites
Size
≈ €290,000turnover 2025, estimated
Staff
0.3 FTE
Equity
€43,688
Profit
€34,521
Turnover estimated from the gross margin
Financial health
54 Fair Checked score 2025
Bankruptcy probabilitywithin 12 months
2.1%
Structure
2025 accounts filed 27 days late
Why 54raises riskFounded in 2025Sector: Retail trade (NACE 47)Size: total assets €258,7102 establishment unitsShow the evidence

Checked score

Score 2025
54 / 100
Fair
Probability in this band: 1.5% to 4.2%
Financially better than 49% of its sector peers (NACE 47, micro)
Every signal that counts is listed under Signals.
Financial strength
Average
Solvency 42
equity 16.9% of total assets
Liquidity 38
short-term debt 47.3% · cash 9.0%
Profitability 85
return on assets 13.3%
Bankruptcy probability, 12 months
2.1% Moderate
0%0.5%1.5%4%10%≥ 25%

About 2 in 100 comparable companies go bankrupt within 12 months (an estimate).

Sector median 0.6% (40,259 companies, NACE 47, micro)
Last 24 months 08-2026: 2.2%highest value 09-2026: 1.8%▼ -0.4 percentage points vs 08-2026lowest value 10-2026: 2.1%▲ +0.3 percentage points vs 09-2026
Credit of up to €2,000 on 30-day terms is acceptable
Liquidity tight (current ratio 1.34, below the usual 1.5; short-term debt: 47.3% and cash: 9% of total assets), and 83.1% of the assets are financed with debt and provisions.
How it is calculated

The band follows from the bankruptcy probability, on a scale where 10 more points roughly halve it:

75-100 Excellent under 0.55%
60-74 Healthy 0.55% to 1.5%
45-59 Fair 1.5% to 4.2%
25-44 Weak 4.2% to 15.0%
0-24 Critical over 15.0%

Where the company stands within its band depends half on the bankruptcy probability and half on how it does against its sector peers (NACE 47, micro): better than 33% on solvency, 35% on liquidity and 80% on profitability.

The bankruptcy probability was computed on 28-10-2026 by the bankruptcy model of 2 October 2026, which learns from Belgian bankruptcies and reads the registers, the annual accounts and the Belgian Official Gazette.

Some facts cap the score, however low the probability. Negative or zero equity, a heavy loss, a special status in the KBO, one missing filing or accounts filed more than 90 days late hold it at Fair at most (59); two missing filings, at Weak (44). An ongoing judicial reorganisation or the company's end (bankruptcy, dissolution, liquidation) holds it at Critical at most (24).

Credit check for your own amount and term

Show the recommended maximum and see how the verdict changes with amount, term and advance.

Signals

Five signals.
raises risk
raises risk · Founded in 2025
Companies of this age fail more often than older ones; how much that weighs depends on the rest of its profile.
KBO
raises risk · Sector: Retail trade (NACE 47)
KBO
raises risk · Size: total assets €258,710
Companies of this size fail more often; how much that weighs depends on the rest of its profile.
NBB · annual accounts
raises risk · 2 establishment units
KBO · seat and establishments
raises risk · 2025 accounts filed 27 days late
The financial year that closed on 31-12-2025 was due by 31-07-2026 and was filed on 27-08-2026, 27 days later. Nearly half (47%) of Belgian companies file late; of those that file 1 to 90 days late, 2.0% are now bankrupt, dissolved or in another special legal status, against 1.66% of all filers. A delay like this does not count in the score.
NBB · 1 filing
Deviation from the deadline
2025
27 days late
← before the deadline after the deadline →
Searched, nothing found (1)
neutral · No strike-offs in the KBO publications
Searched since incorporation in 2025.
KBO publications · our coverage
  1. Annual accounts filedfinancial year 2025 · micro…
  2. IncorporationAppointment: FATHALLAH Ibtihej (director) ·…

Key points

  • Founded 15 months agofounded 03-07-2025 15 months View
  • Positive: Among the best 18% on net resultsector median €5,089 · 22,613 companies €34,521 View
  • One director decidessole director in office 1 View

By topic

Financials

Financial year
2025
Total assets
€258,710
Profit
€34,521
Solvency
16.9%
Go to Financials

Company details

Sites
2
Legal form
Private limited company
Activity
Retail sale of pharmaceutical productsNACE 47730
Founded
03-07-2025
Year ends
31-12
Peppol
Reachable for e-invoices
Go to Company details

Articles of association

Provisions read
40
Who signs
Each director alone
Annual meeting
Last Friday of May at 19:00
Purpose
“Toutes opérations généralement quelconques, industrielles, commerciales, financières…” (deed in French)
Go to Articles of association

Key facts about LINDA PHARMA

What is the company number of LINDA PHARMA?
1025.098.275. In Belgium the VAT number is the company number with BE in front: BE 1025.098.275.
Where is LINDA PHARMA based?
The registered office is at Leopoldstadplein 16, 1040 Etterbeek.Company details
What does LINDA PHARMA do?
According to the KBO register, the main activity is retail sale of pharmaceutical products (NACE 47730).
What is the legal form of LINDA PHARMA?
Private limited company (BV).
When was LINDA PHARMA founded?
On 03-07-2025.
Is LINDA PHARMA still active?
Yes, LINDA PHARMA is an active enterprise in the KBO register.
How many employees does LINDA PHARMA have?
On average 0.3 full-time equivalents in financial year 2025, according to the filed annual accounts.Financials
What is the turnover of LINDA PHARMA?
Not stated in the processed annual accounts. The abridged format for small companies does not require turnover.
Is LINDA PHARMA profitable?
In financial year 2025, LINDA PHARMA made a profit of €34,521.
Where can I find the annual accounts of LINDA PHARMA?
LINDA PHARMA filed 1 annual account with the National Bank of Belgium, for financial year 2025.

Companies related to LINDA PHARMA

Go further with this company

How much credit can you give this customer, and on what payment terms?Credit check What should you check before you do business with this company?Supplier due diligence Can you accept this company as a client under the anti-money-laundering law?AML client file Which of your other customers can you e-invoice via Peppol?Peppol check How does this company compare with its sector?Sector benchmark Is the workforce growing, and do people stay?Employer check

Your own company? See how customers, suppliers and banks see it and what to improve first.

Investigating this company? Keep it with today's facts in a case file.

We would like to set cookies. That happens only with your consent. What we measure